Skip to main content

Advertisement

SpringerLink
Log in

Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Identification of gastric cancer-related molecules is necessary to elucidate the pathological mechanisms of this heterogeneous disease. The purpose of this study was to identify novel genes associated with aggressive phenotypes of gastric cancer.

Methods

Global expression profiling was conducted using tissues from four patients with metastatic gastric cancer to identify genes overexpressed in gastric cancer. Fifteen gastric cell lines and 262 pairs of surgically resected gastric tissues were subjected to mRNA expression analysis. The contribution of the candidate gene on gastric cancer cell proliferation, invasion, adhesion, and migration were evaluated using small interfering RNA.

Results

DnaJ heat shock protein family (Hsp40) member C12 (DNAJC12) was identified as a candidate gene by transcriptome analysis. In clinical samples, DNAJC12 mRNA levels were higher in gastric cancer tissues compared with normal adjacent tissues. Patients with high DNAJC12 expression showed significantly shorter overall survival in our cohort and in the extra-validation cohort analyzed by a published microarray dataset. High DNAJC12 expression in gastric cancer tissues was significantly associated with lymphatic involvement, infiltrative growth type, lymph node metastasis, and advanced stage and was identified as an independent prognostic factor for overall survival in multivariable analysis. Increased expression of DNAJC12 was found in 12 of 14 examined gastric cancer cell lines. Knockdown of DNAJC12 expression significantly decreased the proliferation and invasion abilities of gastric cancer cells.

Conclusions

Our findings support DNAJC12 as a candidate gene associated with aggressive phenotypes of gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–64.

    Article  CAS  PubMed  Google Scholar 

  2. Kanda M, Kodera Y, Sakamoto J. Updated evidence on adjuvant treatments for gastric cancer. Expert Rev Gastroenterol Hepatol. 2015;9:1549–60.

    Article  CAS  PubMed  Google Scholar 

  3. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014;11:664–74.

    Article  CAS  PubMed  Google Scholar 

  5. Kanda M, Kodera Y. Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol. 2015;21:9838–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Duraes C, Almeida GM, Seruca R, Oliveira C, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch. 2014;464:367–78.

    Article  CAS  PubMed  Google Scholar 

  7. Shevtsov M, Multhoff G. Heat shock protein-peptide and HSP-based immunotherapies for the treatment of cancer. Front Immunol. 2016;7:171.

    PubMed  PubMed Central  Google Scholar 

  8. Straniero L, Guella I, Cilia R, et al. DNAJC12 and dopa-responsive nonprogressive parkinsonism. Ann Neurol. 2017;82:640–6.

    Article  CAS  PubMed  Google Scholar 

  9. Kanda M, Shimizu D, Tanaka H, et al. Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget. 2016;7:13667–79.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kanda M, Nomoto S, Oya H, et al. The expression of melanoma-associated antigen d2 both in surgically resected and serum samples serves as clinically relevant biomarker of gastric cancer progression. Ann Surg Oncol. 2016;23 Suppl 2:214–21.

    Article  Google Scholar 

  11. Liu JY, Peng CW, Yang XJ, Huang CQ, Li Y. The prognosis role of AJCC/UICC 8(th) edition staging system in gastric cancer, a retrospective analysis. Am J Transl Res. 2018;10:292–303.

    PubMed  PubMed Central  Google Scholar 

  12. Kanda M, Murotani K, Kobayashi D, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: a propensity score matching analysis. Surgery. 2015;158:1573–80.

    Article  PubMed  Google Scholar 

  13. Foo M, Leong T. Adjuvant therapy for gastric cancer: current and future directions. World J Gastroenterol. 2014;20:13718–27.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Szasz AM, Lanczky A, Nagy A, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1065 patients. Oncotarget. 2016;7:49322–33.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kanda M, Shimizu D, Fujii T, et al. Function and diagnostic value of Anosmin-1 in gastric cancer progression. Int J Cancer. 2016;138:721–30.

    Article  CAS  PubMed  Google Scholar 

  16. Kanda M, Shimizu D, Tanaka H, et al. Significance of SYT8 for the detection, prediction, and treatment of peritoneal metastasis from gastric cancer. Ann Surg. 2018;267:495–503.

    Article  PubMed  Google Scholar 

  17. Shimizu D, Kanda M, Tanaka H, et al. GPR155 serves as a predictive biomarker for hematogenous metastasis in patients with gastric cancer. Sci Rep. 2017;7:42089.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kanda M, Tanaka C, Kobayashi D, et al. Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer. Int J Cancer. 2016;139:2290–8.

    Article  CAS  PubMed  Google Scholar 

  19. Miwa T, Kanda M, Tanaka H, et al. FBXO50 enhances the malignant behavior of gastric cancer cells. Ann Surg Oncol. 2017;24:3771–9.

    Article  PubMed  Google Scholar 

  20. Matz JM, Blake MJ, Tatelman HM, Lavoi KP, Holbrook NJ. Characterization and regulation of cold-induced heat shock protein expression in mouse brown adipose tissue. Am J Physiol. 1995;269:R38–47.

    CAS  PubMed  Google Scholar 

  21. Ikwegbue PC, Masamba P, Oyinloye BE, Kappo AP. Roles of heat shock proteins in apoptosis, oxidative stress, human inflammatory diseases, and cancer. Pharmaceuticals (Basel). 2018;11:2.

    Article  CAS  Google Scholar 

  22. Laplante AF, Moulin V, Auger FA, et al. Expression of heat shock proteins in mouse skin during wound healing. J Histochem Cytochem. 1998;46:1291–301.

    Article  CAS  PubMed  Google Scholar 

  23. Johnston CL, Marzano NR, van Oijen AM, Ecroyd H. Using single-molecule approaches to understand the molecular mechanisms of heat-shock protein chaperone function. J Mol Biol. 2018;430:4525–46.

    Article  CAS  PubMed  Google Scholar 

  24. Tsan MF, Gao B. Heat shock protein and innate immunity. Cell Mol Immunol. 2004;1:274–9.

    Google Scholar 

  25. Chen B, Feder ME, Kang L. Evolution of heat-shock protein expression underlying adaptive responses to environmental stress. Mol Ecol. 2018;27:3040–54.

    Article  PubMed  Google Scholar 

  26. Haug M, Schepp CP, Kalbacher H, Dannecker GE, Holzer U. 70-kDa heat shock proteins: specific interactions with HLA-DR molecules and their peptide fragments. Eur J Immunol. 2007;37:1053–63.

    Article  CAS  PubMed  Google Scholar 

  27. Lee MS, Lee J, Lee S, et al. Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer. Oncotarget. 2018;9:7961–7974.

    PubMed  PubMed Central  Google Scholar 

  28. Shen H, Mu C, Wu X, et al. Chemotherapy sensitizes therapy-resistant cells to mild hyperthermia by suppressing heat shock protein 27 expression in triple negative breast cancer. Clin Cancer Res. 2018;24:4900–12.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Blau N, Martinez A, Hoffmann GF, Thony B. DNAJC12 deficiency: a new strategy in the diagnosis of hyperphenylalaninemias. Mol Genet Metab. 2018;123:1–5.

    Article  CAS  PubMed  Google Scholar 

  30. De Bessa SA, Salaorni S, Patrao DF, Neto MM, Brentani MM, Nagai MA. JDP1 (DNAJC12/Hsp40) expression in breast cancer and its association with estrogen receptor status. Int J Mol Med. 2006;17:363–7.

    PubMed  Google Scholar 

  31. He HL, Lee YE, Chen HP, et al. Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Exp Mol Pathol. 2015;98:338–45.

    Article  CAS  PubMed  Google Scholar 

  32. Choi J, Djebbar S, Fournier A, Labrie C. The co-chaperone DNAJC12 binds to Hsc70 and is upregulated by endoplasmic reticulum stress. Cell Stress Chaperones. 2014;19:439–46.

    Article  CAS  PubMed  Google Scholar 

  33. Wegele H, Muller L, Buchner J. Hsp70 and Hsp90: a relay team for protein folding. Rev Physiol Biochem Pharmacol. 2004;151:1–44.

    Article  CAS  PubMed  Google Scholar 

  34. Jin H, Xie Q, Guo X, et al. p63alpha protein up-regulates heat shock protein 70 expression via E2F1 transcription factor 1, promoting Wasf3/Wave3/MMP9 signaling and bladder cancer invasion. J Biol Chem. 2017;292:15952–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Beere HM, Wolf BB, Cain K, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol. 2000;2:469–75.

    Article  CAS  PubMed  Google Scholar 

  36. Singh S, Suri A. Targeting the testis-specific heat-shock protein 70-2 (HSP70-2) reduces cellular growth, migration, and invasion in renal cell carcinoma cells. Tumour Biol. 2014;35:12695–706.

    Article  CAS  PubMed  Google Scholar 

  37. Mohammad RM, Muqbil I, Lowe L, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015;35 Suppl:S78–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan

    Yasuo Uno MD, Mitsuro Kanda MD, PhD, FACS, Takashi Miwa MD, Shinichi Umeda MD, Haruyoshi Tanaka MD, Chie Tanaka MD, PhD, Daisuke Kobayashi MD, PhD, Masaya Suenaga MD, PhD, Norifumi Hattori MD, PhD, Masamichi Hayashi MD, PhD, Suguru Yamada MD, PhD, FACS, Goro Nakayama MD, PhD, Michitaka Fujiwara MD, PhD & Yasuhiro Kodera MD, PhD, FACS

Authors
  1. Yasuo Uno MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsuro Kanda MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Miwa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinichi Umeda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haruyoshi Tanaka MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chie Tanaka MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daisuke Kobayashi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masaya Suenaga MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Norifumi Hattori MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masamichi Hayashi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Suguru Yamada MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Goro Nakayama MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Michitaka Fujiwara MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yasuhiro Kodera MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitsuro Kanda MD, PhD, FACS.

Ethics declarations

Disclosures

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 43 kb)

Supplementary material 2 (DOCX 21 kb)

Supplementary material 3 (DOC 51 kb)

10434_2018_7149_MOESM4_ESM.tif

Supplementary Fig. 1 (a) Expression analyses of DNAJC12 in clinical samples from 262 gastric cancer patients. ROC curve analysis revealed that the AUC value of DNAJC12 levels was 0.606 for detection of mortality of recurrence, and the optimal cutoff value was 0.00925. (b) Expression analysis of DNAJC12 in gastric cancer cell lines. DNAJC12 mRNA levels were detected in differentiated and undifferentiated gastric cancer cell lines and the control FHs74 epithelial cell line (TIFF 6033 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uno, Y., Kanda, M., Miwa, T. et al. Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer. Ann Surg Oncol 26, 836–844 (2019). https://doi.org/10.1245/s10434-018-07149-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-07149-y

Search

Navigation